Clinical trials
Systemic Lupus Erythematosus clinical trials
Below are recruiting systemic lupus erythematosus clinical trials, each written for real people, not researchers. We’re tracking 268 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05688696RecruitingPhase 2
Testing a drug called orelabrutinib for lupus symptoms in adults
This Phase 2 trial studies whether orelabrutinib can improve systemic lupus erythematosus (SLE) and check its safety. It may help people with active lupus who are already on stable lupus medicines.
Bengbu, AnhuiAges 18–75 - NCT05698173Recruiting
Study of lupus and accelerated aging
This study looks at how lupus relates to “accelerated aging” and may help researchers better understand disease effects over time. You might be able to join if you have systemic lupus and are able to consent and participate.
BordeauxAges 18–60 - NCT05714930Recruiting
Treating lupus symptoms to a clear goal
This study looks at a “treat-to-target” approach for people with systemic lupus erythematosus (SLE) to help control symptoms to a specific goal. It may help guide medication changes when lupus is not fully calm yet.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT05859191Recruiting
Study of immune cell markers in people with lupus
This study looks at how certain immune cells (natural killer T cells) behave in people with systemic lupus, by measuring specific immune receptor markers in blood. It may help researchers better understand lupus and how it can connect with other conditions like antiphospholipid syndrome or Sjögren’s.
ToursAges 18 years+ - NCT05916781RecruitingPhase 4
Lowering steroids with mycophenolate and tacrolimus for lupus kidneys
This study tests whether using mycophenolate mofetil plus tacrolimus can help people with lupus nephritis safely lower (taper) their prednisone to a low dose. It is designed for people whose kidney lupus has been well-controlled for at least 6 months.
BeijingAges 18–65 - NCT05927688Recruiting
Using patient reports to adjust treatment for autoimmune diseases
This study looks at whether doctors consider patient “electronic reports” (completed online/phone) when deciding how often to change treatment. It may help improve how well treatment plans match how patients feel over time.
StrasbourgAges 18 years+ - NCT05934149Recruiting
Lupus health registry that stores samples for future research
This study keeps a long-term record of people with lupus (systemic lupus erythematosus) and collects samples so researchers can study the disease better. You may be able to join if you meet lupus diagnosis criteria, are not pregnant, and can follow the study visits and consent process.
Birmingham, AlabamaAges 18–110 - NCT05988216Recruiting
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of immune cell therapy (CAR-T cells) for people with lupus that has not responded well to standard treatments. It aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18–65 - NCT06010472RecruitingEarly Phase 1
Car-NK cell therapy for lupus
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
ShanghaiAges 18–65 - NCT06032923RecruitingPhase 1/Phase 2
Does vitamin B3 boost help lupus symptoms?
This study tests whether a form of vitamin B3, called nicotinamide riboside, can improve immune function and reduce inflammation in women with mild to moderate lupus. It may help understand if boosting NAD+ levels offers a new way to manage the disease.
Bethesda, MarylandAges 18–120 - NCT06106906RecruitingPhase 1/Phase 2
CD19 CAR-T for Active Lupus
This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.
Wuhan, HubeiAges 18–70 - NCT06106893RecruitingPhase 1/Phase 2
Study of CD19 CAR-γδT cells for active lupus
This trial is testing a new type of immune cell therapy (called CD19 universal CAR-γδT cells) for people with active lupus that hasn't been well controlled by standard treatments. The goal is to see if these specially designed cells can calm the immune system and reduce lupus symptoms.
Wuhan, HubeiAges 18–70 - NCT06121297RecruitingPhase 1/Phase 2
CABA-201 for active lupus
This trial tests a new treatment called CABA-201, which is a type of immune cell therapy (CAR T cells) for people with active lupus. The goal is to see if it's safe and can help control lupus symptoms.
Orange, CaliforniaAges 18–65 - NCT06166199Recruiting
High-intensity interval training for lupus patients
This study tests whether high-intensity interval training (short bursts of intense exercise) can help people with systemic lupus erythematosus (SLE, an autoimmune disease). It aims to see if this type of exercise is safe and improves symptoms.
Stockholm, HuddingeAges 18 years+ - NCT06232304Recruiting
Program for young people with childhood lupus
This study tests a program to help teenagers and young adults with childhood-onset lupus manage symptoms like fatigue, sadness, or pain. It aims to improve daily life and well-being.
Birmingham, AlabamaAges 12–22 - NCT06308770Recruiting
Online group program for lupus fatigue
This trial tests a new online group program to help people with lupus manage chronic fatigue. Participants are randomly assigned to either the program or standard care, and all complete questionnaires online.
EdinburghAges 18–85 - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70 - NCT06857214RecruitingPhase 1
GNC-038 antibody study for moderate to severe lupus
This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06340750RecruitingPhase 1
BAFF CAR-T cells for lupus that hasn't improved with standard treatments
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
Columbus, OhioAges 18–65 - NCT06347718RecruitingPhase 1/Phase 2
Car-T cells for autoimmune disease
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Erlangen, BavariaAges 18 years+ - NCT06349343RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
WuhanAges 18–70 - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT06365359Recruiting
Lupus and pesticide exposure in Martinique
This study looks at how exposure to a pesticide called chlordecone might affect people with lupus in Martinique. Researchers want to understand if there is a link between the chemical and lupus symptoms or kidney problems.
Fort-de-FranceAges 18 years+ - NCT06379646Recruiting
YTS109 cell therapy for autoimmune disease
This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic lupus erythematosus?
- Yes. Clin2 currently lists 268 recruiting systemic lupus erythematosus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic lupus erythematosus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic lupus erythematosus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.